JaLCDOI 10.18926/AMO/56652
FullText URL 73_2_161.pdf
Author Okamoto, Sachiyo| Matsuoka, Ken-ichi| Sakamoto, Maiko| Usui, Yoshiaki| Fujiwara, Yuki| Kondo, Takumi| Tani, Katsuma| Saeki, Kyosuke| Meguri, Yusuke| Asada, Noboru| Ennishi, Daisuke| Nishimori, Hisakazu| Fujii, Keiko| Fujii, Nobuharu| Maeda, Yoshinobu|
Abstract Second allogeneic stem cell transplantation (allo-SCT) is a potentially curative therapy for patients who relapse after first allo-SCT. Human leukocyte antigen (HLA)-haploidentical related donors provide the broad opportunity to conduct second SCT at the appropriate time, but the efficacy of second SCT from haploidentical donors after relapse has not been established. We retrospectively analyzed the records of 33 patients who underwent second SCT. Twenty patients underwent haplo-SCT with low-dose antithymocyte globulin (ATG), and the other 13 patients underwent conventional- SCTs, including HLA-matched related peripheral blood, unrelated bone marrow or cord blood. Three years after the second SCT, the overall survival (OS) and progression-free survival (PFS) of all patients were 32.5% and 23.9%. Multivariate analyses indicated that non-complete response at second SCT, less than 1-year interval to relapse after first- SCT, and total score ≥ 3 on the hematopoietic cell transplantation-specific comorbidity index were significantly associated with a lower PFS rate. The haplo- and conventional- SCT groups showed equivalent results regarding OS, PFS, cumulative incidences of relapse, non-relapse mortality and graft-versus-host disease. The neutropenic period after transplantation was significantly shorter in haplo- SCT than conventional- SCT (10.5 days vs. 16 days, p=0.001). Our analysis revealed that haplo-SCT could be an alternative therapeutic option for relapsed patients after first SCT.
Keywords allogeneic stem cell transplantation haploidentical stem cell transplantation relapse anti-T lymphocyte globulin
Amo Type Original Article
Published Date 2019-04
Publication Title Acta Medica Okayama
Volume volume73
Issue issue2
Publisher Okayama University Medical School
Start Page 161
End Page 171
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2019 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 31015751